Figure 6.
Neutralization of SARS-CoV-2 Omicron variants by individual human sera collected from vaccine recipients (no prior SARS-CoV-2 infection) who received the bivalent mRNA booster as the fourth dose. Eleven human serum samples (each represented by a circle) collected from volunteers who received three doses of monovalent mRNA vaccine and one dose of the bivalent mRNA booster (original SARS-CoV-2 virus + Omicron variant BA.4/5) were analyzed against SARS-CoV-2 614D virus and various Omicron variants using the FRNT assay. All viruses were isolated from clinical specimens. Bars represent GMT with 95% confidence intervals. Significance relative to 614D or BA.4/5 was determined by one-way repeated measures ANOVA with Dunnett correction on log transformed neutralization titers. p values are displayed as ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 and not significant (ns) p > 0.05. GMT and fold change compared to 614D or BA.4/5 are displayed at the top of the plots. The dashed line represents the limit of detection at FRNT50 of 20.